

9TH MICROBIOME R&D & BUSINESS COLLABORATION CONGRESS: ASIA



**5-6 MARCH 2025
WYNDHAM GRAND
ZHAOQING
DOWNTOWN**

Organised by:



Co-hosted with:



WWW.GLOBAL-ENGAGE.COM



Hello & Welcome

Welcome to Global Engage's inaugural microbiome event in China, **Microbiome R&D and Business Collaboration Congress**, taking place in-person on the 5th and 6th of March 2025 at Wyndham Grand Zhaoqing Downtown, Zhaoqing, China.

Co-hosted with the *Handsome Investment Group*, this edition is an excellent platform for researchers and product developers to gain knowledge and explore strategies to turn discoveries into products. It aims to connect the community with investors for commercialization support and provides networking opportunities.

Running on multiple tracks, this conference will showcase unique areas of scientific and business developments in the skin microbiome and microbiome spaces. Key thought leaders will share the latest cutting-edge research, emerging technologies, commercial interest, product development, and regulatory & claim considerations.

Attend this conference to learn from leading scientists, showcase research, and explore industry partnerships and funding. It is an event of utmost importance that you should not miss.

We look forward to seeing you in Zhaoqing, China!

With warm wishes,



Wen Fang Woo

Conference Producer - ASIA

About the Event

Conference synopsis

SKIN MICROBIOME

- Skin microbiome & cosmeceuticals
- Skin health, wellbeing, and microbiome-associated skin disease
- Regulatory landscapes & consumer insights
- Skin immunology
- Latest advances on mapping and profiling technologies
- Role of skin microbiome in precision health
- Aging
- Hair & scalp
- Wound healing

MICROBIOME

- Gut microbiome in health & disease
- Beyond gut & women's health
- Microbiome translational medicine
- Microbiome therapeutics & regulatory & commercialisation
- Microbiome & cancer
- Microbiome data & tools
- Microbiome & pro/pre/postbiotics
- Personalised nutrition and HMO & infant

Poster Presentations

Whether looking for funding, job opportunities or simply wanting to share your work with a like-minded and focused group, poster presentations are an excellent way to join the heart of the congress. Poster presentations are actively encouraged at this event and as such registered academic, industry, and start-up delegates are invited to present 1 poster each for free.

Poster competition

Six poster winners will each receive a cash prize worth USD 500. Two exceptional entries among the six will be selected for a 15-minute speaking position on the program.

Representatives from solution provider organisations or experts already speaking on the program are ineligible to enter the competition but are welcome to present posters at the meeting as normal.

Flash talks

Three 5-minute flash talks are allocated for industry and start-up companies to present an overview of their research poster.

Submission instruction

Poster competition/ presentation abstract submission deadline is on **27th January 2025**. Download poster presentation/competition form [HERE](#)

Contact: haley@global-engage.com for more inquiries

About the Event

Registration:

To register, please visit our **website** or contact Dhevindran at: **Dhevin@global-engage.com**

Media Partners:



Official conference/hotel venue:

Wyndham Grand Zhaoqing Downtown

No.13, Xinghu Road, Duanzhou District,
Zhaoqing, Guangdong, China

肇庆市七星岩温德姆至尊酒店

中国广东省肇庆市端州区星湖大道五段13号



Our Speakers



MARC GÜELL
ICREA Research Professor,
Pompeu Fabra University



QI SU
Assistant Professor
(Research), Chinese University
of Hong Kong



WEILIAN HUNG
Director of Probiotics
Research Center, Yili
Innovation Center



JODI WOAN-FEI LAW
Assistant Professor, University
of Nottingham Ningbo



ANNALISA TERRANEGRA
Principal Investigator,
Sidra Medicine



ALBERT DASHI
CSO & Co-Founder,
Sequential



LARRY WEISS, M.D.
CEO, Symbiome



JOHN COMMON
Deputy Executive Director and
Professor of Cutaneous
Inflammation and Microbiome,
A*STAR Skin Research Labs and
Newcastle University



SIAM POPLUECHAI
Associate Professor, Mae Fah
Luang University



ERIC HUANG CHUN-MING
Chief Scientific Advisor, Yunneng
Biotechnology Co., Ltd



JINZHONG XIAO
Director/Professor,
Morinaga Milk Industry Co., Ltd



AARTHI RAVIKRISHNAN
Scientist, Genome Institute of
Singapore (GIS), A*STAR



MOHD HAFIZ ARZMI
Associate Professor,
International Islamic University
Malaysia



JIA XU
Senior Scientist II, Singapore
Institute for Clinical Sciences,
A*STAR



SANG SUN YOON
Professor and CEO, Yonsei
University College of Medicine and
BioMe Inc



TING FAN LEUNG
Professor, The Chinese University
of Hong Kong



LOH TENG-HERN TAN
Assistant Professor, University
of Nottingham Ningbo



XIAOQUAN SU
Professor, Qingdao University



JIYEON SI
Principal Investigator, Korea
Institute of Science and
Technology (KIST)



SEBASTIAN SCHIDMT
Principal Investigator,
University College Cork



HONGWEI ZHOU
Director, Zhujiang Hospital



SENIOR REPRESENTATIVE
P&G



SENIOR REPRESENTATIVE
Danone

Agenda		Wednesday, Mar 5th, 2025	
0800-0830	Registration & Morning Coffee		
0830-0835	Global Engage & Handsome Investment Group Welcome Address		
0835-0905	Chairperson:		
	Keynote Presentation  JOHN COMMON Deputy Executive Director and Professor of Cutaneous Inflammation and Microbiome, A*STAR Skin Research Labs and Newcastle University THE SKIN MICROBIOME IN CHRONIC INFLAMMATORY SKIN DISEASES The skin is home to millions of bacteria, fungi and viruses that make up the complex communities of our skin microbiota. The composition of these microbial communities differ depending on biogeographical skin location and can remain stable for years. Technological advances in sequencing have allowed researchers to investigate resident microbial population at high resolution providing valuable insights into disease pathogenesis. These culture-independent investigations of the skin microbiome is revealing a much more complex picture of the contribution of species and stains to disease pathogenesis and severity. One of the largest disruptors of our skin microbiome is the occurrence of inflammatory skin diseases such as atopic dermatitis and ichthyosis. With atopic dermatitis being a disorder that effects 1 in 5 children, studies of the skin microbiome is particularly important when considering the paediatric phase of life. Recent studies are unraveling the mechanisms of host-microbe interplay at the skin barrier. Understanding the microbes and their collective contribution to skin health is important for the development of novel therapeutic approaches and interventions for improved relationships with our closest neighbours.		
0905-0935	Keynote Presentation INVITATION OUT		
0935-1005	Solution Provider Presentation For sponsorship opportunities, please contact reuben@global-engage.com		
1005-1055	Morning Refreshments Poster Presentations 1-2-1 Meetings		
1055-1115	MICROBIOTA & SKIN DISEASE		MICROBIOME DATA & TOOLS
	Chairperson:		Chairperson:
	 TING FAN LEUNG Professor, The Chinese University of Hong Kong TBD	 QI SU Assistant Professor (Research), The Chinese University of Hong Kong GUT MICROBIOME MEETS ARTIFICIAL INTELLIGENCE	

1055-1115

Artificial Intelligence (AI) is a powerful tool for gut microbiome. We explored the potential of AI with its application in the crosstalk between gut dysbiosis and Long COVID. We found that gut microbiome during the acute SARS-CoV-2 infection is related to the emergence of Long COVID after viral clearance, and based on this we built a regression model that predicts the length of the viral positive period, a binary model that predicts the risk of Long COVID, a multi-label model that predicts different symptoms, and a multi-class model that distinguishes Long COVID from common human diseases. Our series of studies revealed the significance of AI in understanding the role of gut microbiota in the pathogenesis, diagnosis and therapeutics of Long COVID and provided novel insights into the potential of gut microbiome-targeted applications for Long COVID in the post-COVID era.

1115-1135



MARC GÜELL
ICREA Research Professor, Pompeu Fabra University

MODULATING THE HOST SKIN USING THE SKIN MICROBIOME

We will present our advancements in transforming Cutibacterium acnes into a synthetic biology platform tailored for skin applications. Initially, our focus was on leveraging this bacterium to achieve sustained alterations in the skin's microbiome, utilizing natural variants. The stable environment of its natural habitat, the sebaceous appendices, provides a robust foundation for persistent bioengineering. Our efforts led to notable successful colonization and interesting therapeutic effects.

In recent years, our work has expanded to include the development of robust tools for the precise genetic manipulation of C. acnes. This includes a variety of synthetic biology components, circuit designs, and methodologies for genetic modification. Notably, we have developed several biocontainment approaches for controlled application of genetically altered bacteria. We have engineered and characterized the effectiveness of various synthetic functions, such as sebum regulation, immune system interaction, and sensing.

Our vision is to introduce new functions to human skin by engineering these endogenous microbes.



SEBASTIAN SCHIDMT
Principal Investigator, University College Cork

1135-1150

EARLY CAREER RESEARCHER

This session is allocated for early career researchers to showcase their research at this conference. Please contact wenfang@global-engage.com to submit your interest

EARLY CAREER RESEARCHER



AARTHI RAVIKRISHNAN
Scientist, Genome Institute of Singapore (GIS), A*STAR
**GUT METAGENOMES OF ASIAN OCTOGENARIANS REVEAL
MICROBIAL SPECIES PROMOTING HEALTHY AGING**

While rapid demographic changes in Asia are driving the incidence of chronic diseases related to aging, the limited availability of high-quality in vivo data hampers our ability to understand complex multi-factorial contributions, including gut microbial, to healthy aging. Leveraging the availability of a well-phenotyped cohort of community-living octogenarians in Singapore, we used deep shotgun metagenomic sequencing to do high-resolution taxonomic and functional characterization of their gut microbiomes (n=234). Species-level analysis identified a distinct age-associated shift in Asian gut metagenomes, characterized by a reduction in microbial richness, and enrichment of specific *Alistipes* species (e.g. *Alistipes onderdonkii*). Functional pathway analysis confirmed that these changes correspond to a metabolic switch in aging from microbial guilds that typically produce butyrate in the gut (e.g. *Faecalibacterium prausnitzii*, *Roseburia inulinivorans*) to alternate pathways that utilize amino-acid precursors. Extending these observations to key clinical markers helped identify >15 robust gut microbial associations to cardiometabolic health, inflammation, and frailty, including potential probiotics such as *Parabacteroides goldsteinii* and pathogenic species such as *Dialister invisus*, highlighting the role of the microbiome as biomarkers and potential intervention targets for promoting healthy aging.

1150-1210



JODI WOAN-FEI LAW
Assistant Professor, University of Nottingham Ningbo
**THE GUT-SKIN AXIS: GUT MICROBIOME CONNECTIONS TO
ATOPIC DERMATITIS (ECZEMA)**

Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease that manifests early in life, impacting 15–30% of children and 10% of adults. AD typically starts in childhood, with 60% of patients <1 year of age developing the disease. Recent advancements in research have shed light on the intricate relationship between the gut microbiome and the development of AD, thus, elucidating the concept of the gut-skin axis. Infancy and childhood are critical periods for the development of the gut microbiome, which in turn influences



XIAOQUAN SU
Professor, Qingdao University
**HOST-VARIABLE-EMBEDDING AUGMENTED MICROBIOME-BASED
SIMULTANEOUS DETECTION OF MULTIPLE DISEASES BY DEEP
LEARNING**

Microbiome has emerged as a promising indicator or predictor of human diseases. However, previous studies have typically labeled each specimen as either healthy or with a specific disease, ignoring prevalence of complications or comorbidities in actual cohorts, which may confound the microbial-disease associations. Furthermore, host phenotypes like physiological characteristics and lifestyles can alter microbiome structure, but such information has not yet been fully utilized in

Agenda		Wednesday, Mar 5th, 2025	
		immune system maturation that shapes an individual’s disposition to AD. This bidirectional communication highlights the dynamic complexity of the body’s ecosystem, where perturbations in the gut microbiome can have profound implications on skin health and disease manifestation. This presentation delves into the burgeoning field of research investigating the relationships between the gut microbiome and AD, aiming to understand the underlying mechanisms and potential therapeutic avenues.	data models. To address these issues, a highly explainable deep learning (DL) method called Meta-Spec is proposed. Using a deep neural network (DNN)-based approach, it encodes and embeds refined host variables with microbiome features, enabling the detection of multiple diseases simultaneously. Experiments show that Meta-Spec outperforms regular machine learning (ML) strategies for multilabel disease screening in several cohorts. More importantly, Meta-Spec successfully detects comorbidities that are often missed by other approaches. Hence, these efforts improve the feasibility and sensitivity of microbiome-based disease screening in practical scenarios, representing a significant step toward personalized medicine and better health outcomes.
	1210-1240	Solution Provider Presentation For sponsorship opportunities, please contact reuben@global-engage.com	Solution Provider Presentation For sponsorship opportunities, please contact reuben@global-engage.com
	1240-1340	Lunch Poster Presentations 1-2-1 Meetings	
		WOMEN’S & INFANT HEALTH	PROBIOTICS PERSONALISED NUTRITION HMO
		Chairperson:	Chairperson:
	1340-1400	INVITATION OUT For speaking opportunities, please contact Wen Fang at (Wenfang@global-engage.com)	 SIMON WANG <i>(Reserved)</i> Probiotics Lead – Active Living, Fonterra Group
	1400-1420	 JIA XU Senior Scientist II, Singapore Institute for Clinical Sciences, A*STAR THE HUMAN GUT MICROBIOME IN PREGNANCY AND EARLY LIFE: INSIGHTS FROM THE MULTI-ETHNIC ASIAN COHORTS GUSTO AND S-PRESTO The gut microbiota plays pivotal roles in regulating host metabolism, immune response, and mental health. From birth, maternal microbes seed the neonatal gut, initiating the development of the infant's gut microbiota alongside physiological maturation. This process is foundational to long-term human health. Pregnancy and early infancy are critical periods characterized by rapid metabolic, physiological, and immunological changes, highly sensitive to both intrinsic and extrinsic factors. Understanding the development of the gut microbiome during these stages can enhance our knowledge of developing microbiome-targeted interventions to mitigate risks associated with	 WEILIAN HUNG Director of Probiotics Research Center, Yili Innovation Center THE DEVELOPMENT AND APPLICATION OF NATIVE PROBIOTIC STRAINS IN CHINA In recent years, the overall probiotic fever continues to intensify, and the global probiotic market is advancing steadily and rapidly. It is anticipated that the global market scale of probiotics will reach 111.5 billion US dollars by 2030. From the aspect of the regional market situation, the consumption scale of probiotics in the Asia-Pacific region holds the highest proportion in the world. The structure of the aging and the young has turned into the main potential battleground for the future development of probiotics in China. In response to the market and consumer demands, Yili Probiotic Research Center pools the strength from the upper, middle, and lower reaches of strain research and development, takes the

Agenda		Wednesday, Mar 5th, 2025	
1420-1440	non-communicable diseases. In her presentation, Dr. Jia Xu will elucidate her recent findings on several key aspects of microbiome development: • Changes in women’s gut microbiome from preconception to post-delivery and its link with metabolic health; • The colonization of gut microbiome in early life and how various intrinsic and early-life factors influence their acquisition; • The effects of modern practices on the colonization of beneficial microbes in the infant gut		research and development of Chinese patented probiotics as the direction, and is dedicated to exploring probiotics that are more suitable for the Chinese people.
		SENIOR REPRESENTATIVE Danone	 ANNALISA TERRANEGRA Principal Investigator, Sidra Medicine THE GUT MICROBIOTA AS BIOMARKER OF CLINICAL OUTCOMES IN THE CONTEXT OF TYPE 1 DIABETES Type 1 diabetes (T1D) is one of the common pediatric diseases in Qatar. In a cross-sectional study of 102 pediatric T1D patients, we searched for potential microbial biomarkers of clinical outcomes and explored the role of diet in modulating the biomarkers. Briefly, the genus Akkermansia, a mucin-degrading bacterium, was significantly elevated in the Qatari patients with poorly controlled HbA1c levels (>7.5%) and consuming an Arabic diet. A distinct microbial signature has been associated with high blood pressure (BP>90th percentile), characterized by a reduced Bifidobacterium genus. An integrated analysis of the nutrient intake, gut microbiome, and blood transcriptome discriminated T1D-obese patients (BMI>95th percentile) from non-diabetic obese children. These findings show the strong potential of the gut microbiota as a biomarker of clinical outcomes and will pose the basis for microbiome-based therapies for T1D.
	Solution Provider Presentation For sponsorship opportunities, please contact reuben@global-engage.com		Solution Provider Presentation For sponsorship opportunities, please contact reuben@global-engage.com
	Afternoon Refreshments Poster Presentations 1-2-1 Meetings		
	Chairperson:		
1600-1615	Flash Presentations Three 5-minute flash talks are allocated for industry and start-up companies to present an overview of their research		

Agenda	Wednesday, Mar 5th, 2025
1615-1700	<i>Panel Discussion</i> COMMERCIALISATION: SCIENCE VERSUS CONSUMERS • Recent advances • Strategies for bringing products to market • Application and regulations • Consumer • Future direction
1705	End of Day 1 Dinner Reception All delegates are welcome to join the dinner reception

Agenda		Thursday, Mar 6th, 2025	
0800-0900	Registration & Morning Coffee		
	SKIN MICROBIOME	HUMAN MICROBIOME	
0900-0930	Chairperson:	Chairperson:	
	Keynote Presentation INVITATION OUT	Keynote Presentation  HONGWEI ZHOU Director, Zhujiang Hospital	
0930-1000	Keynote Presentation  LARRY WEISS, M.D. CEO, Symbiome BACK TO HEALTH - AN EVOLUTIONARY BIOLOGY PERSPECTIVE ON THE SKIN MICROBIOME Major Points - Metagenomics and metabolomics of the Yanomami skin microbiome. - Functional anatomy of the ancestral skin microbiome. - Translating the ancestral skin microbiome into safe and effective interventions. The emerging science of the microbiome is still in its infancy, yet it is the driving force behind a transformative scientific revolution. What lies ahead will have broad implications for us as scientists, our companies and academic institutions, our health, and perhaps our survival. It is worth reflecting on where we are today, how we got here, what we have learned so far, and the limitations of our methods and of our vision. I will discuss what we are learning about our biological past from the microbiota of minimally impacted hunter-gatherers and how it challenges our deeply held ideas about human health that may inform our path forward.	Keynote Presentation  JINZHONG XIAO Director and Professor, Morinaga Milk Industry Co., Ltd NEW INSIGHTS INTO THE GUT-BRAIN AXIS: THE GREAT POTENTIAL OF BIFIDOBACTERIUM BREVE MCC1274 TO IMPROVE BRAIN FUNCTION It is well known that the populations of major countries around the world are ageing. Cognitive decline is one of the biggest challenges facing the elderly. The global Alzheimer's population is expected to reach 130 million by 2050. Currently, Alzheimer's disease is prevention-oriented, and once it develops there is no cure yet. On the other hand, the relationship between the gut microbiota and health, referred to as the 'microbiota-gut-brain axis', has attracted much attention. In this context, we identified <i>Bifidobacterium breve</i> MCC1274 in our search for food ingredients that improve cognitive function, which has been shown to be effective in inhibiting cognitive decline and cerebral atrophy in animal models and clinical trials. This presentation describes the effects and mechanisms of action of <i>Bifidobacterium breve</i> MCC1274 in improving cognitive function from the gut to the brain.	
	1000-1030	Solution Provider Presentation For sponsorship opportunities, please contact: reuben@global-engage.com	Solution Provider Presentation For sponsorship opportunities, please contact: reuben@global-engage.com
1030-1120	Morning Refreshments Poster Presentations 1-2-1 Meetings		

COMPANY SPOTLIGHT

MICROBIOME IN HEALTH AND DISEASE - GUT & BEYOND

Chairperson:

Chairperson:

1120-1140

SENIOR REPRESENTATIVE
Handsome investment Group



JIYEON SI
Principal Investigator, Korea Institute of Science and Technology (KIST)
TBD

1140-1200



GRACE PARK *(Reserved)*
VP R&D, HelloBiome

REDEFINING SKIN TYPES THROUGH AI: MICROBIOME-BASED SEGMENTATION FOR PRODUCT INNOVATION AND PERSONALIZATION

The dynamic interplay between the skin microbiome and personal care products is multifaceted and intricate. While these products aim to cleanse, beautify, and protect, they can sometimes disturb the delicate balance of skin microbes, leading to dysbiosis. Recognizing the importance of the microbiome's influence on skin health, our study recruited 1000 participants who completed detailed skin and lifestyle questionnaires and collected skin microbiome samples at home. Through a comprehensive analysis, we observed distinct skin microbiome profiles, classifying various skin types into clusters based on their predominant microbial species, such as Cutibacterium, Corynebacterium, Staphylococcus, and Streptococcus. Our formulating strategy targeted these microorganisms linked to specific skin conditions within each cluster. Our method went beyond selecting active ingredients that modify microbial populations; we carefully adjusted product pH and moisture levels and chose suitable preservatives and ingredients, crafting bespoke solutions for each unique skin profile.



MOHD HAFIZ ARZMI
Associate Professor, International Islamic University Malaysia

HARNESSING THE POWER OF BIOTICS: INNOVATIONS IN ORAL MICROBIOME MANAGEMENT FOR OPTIMAL HEALTH

Probiotics, prebiotics, and postbiotics are revolutionizing oral health care, offering cutting-edge solutions for preventing and managing oral diseases. Probiotics, composed of live beneficial bacteria, inhibit harmful pathogens, reducing incidences of dental caries, periodontitis, and halitosis. Prebiotics, non-digestible fibers, selectively nourish these beneficial bacteria, fostering a robust and balanced oral microbiome. Postbiotics, the metabolic byproducts of probiotics, exhibit powerful antimicrobial, anti-inflammatory, and immunomodulatory properties, further enhancing oral health. This triad of biotics not only disrupts pathogenic biofilms but also promotes oral tissue health and systemic immunity. The integration of these biotics into oral care products represents a paradigm shift towards natural, holistic, and effective dental therapies. At this congress, he will present the latest research, technological advancements, and potential applications of probiotics, prebiotics, and postbiotics, heralding a new era in oral health that is both scientifically groundbreaking and clinically transformative.

1200-1230

Solution Provider Presentation
For sponsorship opportunities, please contact: reuben@global-engage.com

Solution Provider Presentation
For sponsorship opportunities, please contact: reuben@global-engage.com

1230-1250



ALBERT DASHI
CSO & Co-Founder, Sequential



SIAM POPLUECHAI
Associate Professor, Mae Fah Luang University

A TRADITIONAL THAI MEDICINE INTERVENTION FOR NCDS TARGETS GUT

Noncommunicable diseases (NCDs) are the primary cause of morbidity and mortality on a global scale. Globally, type 2 diabetes mellitus (T2DM) has emerged as a significant public health concern. In Thailand, patients with noncommunicable diseases (NCDs) frequently combine conventional medicine with traditional Thai medicine. Recent research suggests that metabolic disorders are influenced by the intestinal microbiota. Numerous studies have indicated that nutraceutical interventions that enhance the microbiota and induce clinical improvements in metabolic diseases have expanded significantly. Mathurameha (MT) is an oral dosage formulation that is utilized to treat patients with T2DM. It is composed of 26 medicinal plants. In this investigation, the gut microbiota, bioactive compounds, toxicity, and bioactivities of MT were investigated using multi-omics analysis. The LC-MS-qTOF analysis of MT revealed that the metabolites contain phenolic compounds and terpenoids. In vitro cell culture analysis demonstrated bioactive compounds showed α -glucosidase inhibition activity and stimulated the percent of glucose consumption. An investigation was conducted to examine the impact of MT on induced diabetic rats and patients with T2DM. The study revealed that MT intervention resulted in a significant reduction in blood glucose levels in both diabetic rats and T2DM patients, compared to the control group. In addition, MT interventions alter the composition of gut flora and fecal metabolites. The findings indicated that Mathurameha might help reduce blood glucose levels in T2DM through several mechanisms.

1250-1310



ERIC HUANG CHUN-MING
Chief Scientific Advisor, Yunneng Biotechnology Co., Ltd
**SKIN S. EPIDERMIDIS, RIBOTYPES, PHENOTYPES AND
BIO-ENGINEERING AS THERAPEUTICS**

Different subtypes of *Staphylococcus epidermidis* (S. epidermidis) have been isolated from various resources in our laboratories. Ribotyping these S. epidermidis was conducted by deep learning neural network. Phenotyping these bacterial subspecies were achieved by biological assays in vitro and in vivo. Several SCFA-, carotenoids- and/or electrons-producing S. epidermidis was characterized. To non-genetically modify skin bacteria as bio-therapeutics, S. epidermidis bacteria were uploaded carotenoids (beta-carotene) on their membranes. Provision of external carotenoids to S. epidermidis substantially

Senior Representative (Reserved)
P&G

Agenda	Thursday, Mar 6th, 2025	
	elevate the transcriptional expression of the NDH-2, and promote the electron production. Inoculation of carotenoid-laden bacteria onto the UV-irradiated mouse skin significantly diminished reactive oxygen species (ROS), demonstrating its beneficial effect on combating Redox imbalance. These carotenoids-laden S. epidermidis bacteria become new therapeutics for treatment of redox imbalance-associated human disorders such as cancer, aging, infection and inflammation.	
1310-1410	Lunch Poster Presentations 1-2-1 Meetings	
	HAIR & SCALP MICROBIOME WOUND HEALING	MICROBIOME IN THERAPEUTICS DEVELOPMENT
1410-1425	Chairperson:	Chairperson:
	Poster Winner Presentation Poster winners will receive a cash prize worth USD 500 and a 15-minute speaking position on the program (eligible for non-vendor authors and registered delegates only)	Poster Winner Presentation Poster winners will receive a cash prize worth USD 500 and a 15-minute speaking position on the program (eligible for non-vendor authors and registered delegates only)
1425-1445	LOH TENG-HERN TAN Assistant Professor, University of Nottingham Ningbo INNOVATIVE WOUND DRESSINGS: USE OF PROBIOTICS FOR ENHANCED HEALING The use of probiotics in wound dressings is emerging as a novel approach in the field of wound care. Probiotics, with their antimicrobial and anti-inflammatory properties, offer a unique advantage in promoting wound healing and preventing infections. This presentation delves into the development and application of probiotic-infused wound dressings, examining how these bioactive materials support the healing process. Key mechanisms include the suppression of pathogenic bacteria, enhancement of the skin's natural microbiome, and stimulation of tissue regeneration. Clinical trials and experimental studies demonstrating the effectiveness of probiotic dressings in accelerating wound closure and improving healing outcomes will be highlighted. This innovative approach has the potential to revolutionize wound care, offering a promising alternative to conventional treatments.	SANG SUN YOON Professor and CEO, Yonsei University College of Medicine and BioMe Inc GENETICALLY ENGINEERED BACTERIA FOR THE TREATMENT OF HYPERURICEMIA Hyperuricemia (HUA), i.e. increased serum uric acid (UA) concentration, is a common problem in clinical practice. It is estimated to occur in approximately 8.9% to 24.4% of the general population. HUA causes gout and it also plays a role in the pathogenesis of chronic kidney disease, hypertension, cardiovascular disease and heart failure. Currently treatments of HUA is inadequate as small molecule drugs in treating gout have severe side effects. We aim to develop live bacterial therapeutics in the management of HUA. E. coli Nissel 1917 was engineered to overexpress a fungi uricase. Engineered bacteria showed activity in breaking down uric acid in vitro. Furthermore, protein structure directed mutations were made for the uricase to have stronger UA breaking activity. A xanthine oxidase gene knockout was also carried out to block UA formation in engineered strains. Strains with different combinations of mutant genes and knockout showed different degree of UA lowering activity in in vitro or in vivo assays. One strain was selected for further development as it strongly lowered blood uric acid level in hyperuricemia model animals.

Agenda		Thursday, Mar 6th, 2025	
1445-1505	Senior Representative (<i>Reserved</i>) J&J	 YONG-LIANG ZHU CEO & Founder, PrecisionBio Inc GENETICALLY ENGINEERED BACTERIA FOR THE TREATMENT OF HYPERURICEMIA Hyperuricemia (HUA), i.e. increased serum uric acid (UA) concentration, is a common problem in clinical practice. It is estimated to occur in approximately 8.9% to 24.4% of the general population. HUA causes gout and it also plays a role in the pathogenesis of chronic kidney disease, hypertension, cardiovascular disease and heart failure. Currently treatments of HUA is inadequate as small molecule drugs in treating gout have severe side effects. We aim to develop live bacterial therapeutics in the management of HUA. E. coli Nissel 1917 was engineered to overexpress a fungi uricase. Engineered bacteria showed activity in breaking down uric acid in vitro. Furthermore, protein structure directed mutations were made for the uricase to have stronger UA breaking activity. A xanthine oxidase gene knockout was also carried out to block UA formation in engineered strains. Strains with different combinations of mutant genes and knockout showed different degree of UA lowering activity in in vitro or in vivo assays. One strain was selected for further development as it strongly lowered blood uric acid level in hyperuricemia model animals.	
	Senior Representative (<i>Reserved</i>) Unilever	 YAN TAN (<i>Reserved</i>) CEO, XBiome	
	1525	End of Day 2	

Post Conference Event

Tour to Songshan Lake Scipolis

Date: 7th MARCH 2025

Time: 8:00 - 12:00pm (half-day tour)

Transportation: Provided by organizer

Agenda

8:00 - 10:30 AM	Depart from Wydham Grand Downtown Zhaoqing hotel to Songshan Lake Scipolis
10:30 - 12:00 PM	Site visit and exchange session
12:00 - 14:00 PM	Lunch
14:00 - 16:30 PM	To Guangzhou Baiyun International Airport

A limited number of seats is available and they will be granted on a first-come-first-served basis.



Songshan Lake Scipolis is situated in the core area of the Dongguan Songshan Lake Biomedical Industry Base. The venue is affiliated with various service platforms, enterprise clusters, industry associations, and universities, as well as multiple provincial and municipal key laboratories and technical research centers. It offer a comprehensive integration of production, life, and ecology, providing a wide range of professional services for enterprises and institutions. These services include talent recruitment and training, finance and investment support, intellectual property protection, market channel development and achievement transformation. Additionally the venue can customize to high-standard industrial spaces to meet the specific needs of enterprises and institutions.

MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

Additional Information

Transportation options:

By car/taxi from Guangzhou Baiyun International Airport ↔ hotel.

Taxis are abundant and easily accessible from the airport. It takes 1.5 hours to reach the hotel, with the cost ranging from approximately USD42 ~ USD55 per ride.

Car rentals - there are numerous rental car agencies throughout the region, with several located at the airport.

By metro/bullet train from Guangzhou Baiyun International Airport ↔ hotel 

Disembark Guangzhou East Railway Station from airport T1 (Airport South Station) or T2 (Airport North Station) using metro line 3. The duration is about 37-min, with train interval of 7-min.

By taxi, the trip to Guangzhou East Railway Station takes about 40-min.

From Guangzhou East Railway Station, take a bullet train to Zhaoqing East Railway Station. This journey takes about 30 minutes. The hotel is 27 kilometers from Zhaoqing East Railway Station.

Shuttle Service:


Shuttle bus will be provided from Guangzhou Baiyun International Airport to the conference hotel. The schedule will be provided closer to event date.

Discover Zhaoqing:

Zhaoqing located in the central-west part of Guangdong province, is one of the National Famous Historical and Cultural Cities and the Top Tourist Cities of China. Also known as the “capital of inkstones in China”, Zhaoqing is rich in tourism resources, where a long tourism corridor has been developed, with the Xinghu Scenic Area as the centre and numerous tourist attractions along Xijiang and Suijiang.

Admire the hundreds of Tang Dynasty inscriptions decorating the adjacent Seven Star Crag, check out the rare red-crowned cranes in Xingu Wetland Park, and see the spectacular waterfall and Buddhist temple of Qingyun on a hike at Dinghu Mountain.

[Discover more](#)



Additional Information

Visa application:

If you are attending from a country requiring a visa, please be sure to apply early and complete all required fields. Applications may be denied if necessary information is not included when submitted. We recommend applying for your visa as early as possible.

[Learn more](#)

Visa exemption program:

From March 14, 2024 to December 31, 2025, China has decided to implement a unilateral visa-free policy for ordinary passport holders from twelve countries: **Germany, France, Italy, the Netherlands, Spain, Malaysia, Switzerland, Ireland, Hungary, Austria, Belgium and Luxembourg**. Citizens holding ordinary passports from the above countries who come to China for business, tourism, family visit and transit purposes for no more than 15 days can enter China without a visa. However, it is advisable to confirm visa requirements with your local embassy. Individuals from the above-mentioned countries who do not meet the conditions for visa exemption still need to apply for a visa before entering China.

[Learn more](#)

Invitation letter:

Please contact **haley@global-engage.com** to request an invitation letter needed to begin your visa application process.

Upcoming Events

20 20
24⁻ 25

**21-22
NOV**

2nd Spatial Biology Congress Asia

LKC School of Medicine, NTU, Singapore
Co-hosted with Genome Institute of Singapore, A*STAR

3rd Cell & Gene Therapy Research & Development Congress Asia

Singapore

**10-11
APR**

**8-9
MAY**

9th Microbiome R&D and Business Collaboration Congress: Asia

Singapore

Spatial Biology Congress: CHINA

Guangzhou, China

**26-27
JUN**

**10-11
JUL**

2nd Single Cell Congress Asia

Hong Kong